Thomas Hofstaetter, PhD President and Chief
Executive
Officer
Prior to
joining
VaxInnate,
Dr.
Hofstaetter
spent
more
than 30
years in
leadership
positions
at
research-based
pharmaceutical
companies.
Alan Shaw Ph.D. Chief
Scientific
Officer
and
Chairman
of the
Board
Dr. Shaw joined VaxInnate from the Merck Vaccine Research Division where he was Executive Director of MVD's.
Andrew Drechsler Chief Financial Officer
Andrew Drechsler joined VaxInnate in June 2007, from Valera Pharmaceuticals, Inc. where he served as Chief Financial Officer.
David Taylor MD Chief Medical Officer
Dr. Taylor, Chief Medical Officer, joined VaxInnate in March 2007 from Salix Pharmaceuticals, where he served as Chief Medical Officer and VP, Medical Affairs.
Robert Becker Ph.D. MBA VP Business Development
Dr. Becker joined VaxInnate in December 2005 with 15 years of vaccine development and industry experience at Sanofi Pasteur, leaving as a VP of Corporate Development.
Lynda Tussey, Ph.D. VP
Research
&
Development
Dr. Tussey joined VaxInnate in 2004 from Purdue Pharma where, as Program Leader of Immunotherapeutics , she led the overall development of cancer vaccine program.
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza.
The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy.
VaxInnate was founded by Ruslan Medzhitov and Richard Flavell, both of Yale University and Howard Hughes Medical Institute and leaders in the field of innate immunity.
The company started in 2002 with a research team in New Haven, CT. In 2004, the company expanded and established a development team and corporate headquarters in Cranbury, NJ.
Andrew Drechsler 
David Taylor MD 
Robert Becker Ph.D. MBA 
Lynda Tussey, Ph.D. 
+1 609 860 2277